Exhibit Guide Header

Home , Amgen

16th Annual Meeting August 20 – 21, 2021 Greater Columbus Convention Center Hilton Downtown Columbus Ohio Columbus, Ohio

EXHIBIT GUIDE HEADER

Society Meeting 1 INDUSTRY SUPPORT

INDUSTRY SATELLITE SYMPOSIUM EVENTS Saturday, August 21, 2021

7:00 a.m. - 8:00 a.m. 11:45 a.m. - 12:45 p.m. Industry Satellite Symposium Breakfast Industry Satellite Symposium Lunch Location: A216 Location: A216 Sponsored by: Horizon Therapeutics Sponsored by: Alexion Pharmaceuticals

“Emerging Science: Concomitant Immunomodulation with “Recognizing the Clinical Consequences of Low ALP— Pegloticase” Diagnosing Hypophosphatasia(HPP)”

Dr. Sanjay Chabra Dr. Howard Saal, MD

THANK YOU TO OUR 2021 EXHIBITORS

AbbVie Lilly USA, LLC. Alexion Pharmaceuticals Mallinckrodt Pharmaceuticals Amgen, Inc. Myriad Genetics AstraZeneca Novartis Aurinia Pharmaceuticals, Inc. Pfizer, Inc. Boehringer Ingelheim, Inc. Sanofi Genzyme Bristol-Myers Squibb Scipher Medicine Genentech SoundRheum Diagnostics GlaxoSmithKline TheraTest Laboratories, Inc. Horizon Therapeutics UCB, Inc. Janssen Biotech, Inc. Ultragenyx Pharmaceuticals

Sanofi Genzyme and Regeneron are committed to providing resources to better understand the pathogenesis of rheumatoid arthritis and to research the unmet needs of patients with this disease.

All times are in Eastern Time (US and Canada). All sessions will be located in Hilton/Convention Center Rooms A213-214, unless otherwise noted. FRIDAY, AUGUST 20, 2021 Breakout Sessions OVERVIEW 9:00 a.m. - 11:45 p.m. Rheumatology Issues for Nurses, NPs and PAs Breakout Session 3:00 p.m. - 4:30 p.m. Board of Directors Meeting and Location: Hilton/Convention Center Corporate Members Roundtable* Rooms A215 Location: cc 9:00 a.m. - 9:45 a.m. Management of Vasculitis for Practicing 4:00 p.m. - 7:30 p.m. Registration/Information Desk Open Rheumatologists Location: Hilton/Convention Center Location: Hilton/Convention Center Rooms A210-212 Foyer Rooms A215 Speaker: Alexa Meara, MD, MS 6:30 p.m. - 7:30 p.m. Exhibit Hall Open Location: Hilton/Convention Center 9:45 a.m. - 10:30 a.m. Fibromyalgia: A Practical Approach Rooms A210-212 Location: Hilton/Convention Center Rooms A215 GENERAL SESSION Speaker: David E. Blumenthal, MD 4:30 p.m. - 4:45 p.m. Welcome and Opening Remarks 11:00 a.m. - 11:45 a.m. Scleroderma- An update for President: Stephanie J. Ott, MD, rheumatologists MWRA, FACR Location: Hilton/Convention Center Rooms A215 4:45 p.m. - 5:30 p.m. COVID and autoimmunity: Speaker: Dinesh Khanna, MD, MS the new frontier Speaker: Leonard Calabrese, DO 9:00 a.m. - 9:30 a.m. OAR Advocacy Update Speaker: Stephanie J. Ott, MD, 5:30 p.m. - 6:30 p.m. Thieves' Market MWRA, FACR Moderator: Edward W. Goldberger, MD 9:30 a.m. - 10:00 a.m. OSMA State and Local Update Speaker: Monica Hueckel 6:30 p.m. - 7:30 p.m. Welcome Reception with Exhibitors Location: Hilton/Convention Center 10:00 a.m. - 10:30 a.m. CSRO Advocacy Update Rooms A210-212 Speaker: Madelaine A. Feldman, MD, FACR 7:30 p.m. - 9:00 p.m. OAR Annual Dinner and Lifetime 10:30 a.m. - 11:15 a.m. Networking Break in the Exhibit Hall Achievement Award Presentation Location: Hilton/Convention Center Location: Private Dining Room Rooms A210-212 (Hilton Hotel) 11:15 a.m. - 11:45 a.m. ACR Innovation and Advocacy Speaker: Steve Echard, IOM, CAE SATURDAY, AUGUST 21, 2021 11:45 a.m. - 12:45 p.m. Industry Satellite Symposium Lunch* OVERVIEW Location: Hilton/Convention Center Rooms A216 6:30 a.m. - 4:30 p.m. Registration/Information Desk Open *Not CME Accredited Location: Hilton/Convention Center Rooms A210-212 Foyer 12:45 p.m. - 1:00 p.m. Annual Business Meeting* President: Stephanie J. Ott, MD, 8:00 a.m. - 11:15 a.m. Exhibit Hall Open MWRA, FACR Location: Hilton/Convention Center *Not CME Accredited Rooms A210-212 1:00 p.m. - 1:40 p.m. Scleroderma GENERAL SESSION Speaker: Dinesh Khanna, MD, MS 7:00 a.m. - 8:00 a.m. Industry Satellite Symposium 1:40 p.m. - 2:20 p.m. Microbiome and Autoimmunity Breakfast* Speaker: Gregg J. Silverman, MD Location: Hilton/Convention Center Rooms A216 2:20 p.m. - 3:00 p.m. Research During a Pandemic: Findings *Not CME Accredited from the COVID-19 Global Rheumatology Alliance Registry 8:00 a.m. - 9:00 a.m. Resident/Fellow Poster Session* Speaker: Milena Gianfrancesco, PhD, MPH Location: Hilton/Convention Center Rooms A210-212 Foyer 3:00 p.m. - 3:10 p.m. Networking Break *Not CME Accredited Location: Hilton/Convention Center Rooms A210-212 Foyer 3:10 p.m. - 3:50 p.m. Juvenile Idiopathic Arthritis Speaker: Ed Oberle, MD, RhMSUS 3:50 p.m. - 4:30 p.m. What All Physicians Need to Know About irAEs Speaker: Alexa Meara, MD, MS

Disclaimer Statement Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Ohio Association of Rheumatology, nor does the Ohio Association of Rheumatology provide any warranty as to their accuracy or reliability.

Exhibit Guide Ohio Association of Rheumatology 16th Annual Meeting 3 EXHIBIT HALL FLOOR PLAN

6 8

5 9

26 25 24 23 22

4 10

17 18 19 20 21 3 11

2 12

1 16 15 14 13

Enter Exit

Changing The Course Of Autoimmune Disease

At Aurinia, our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease.

Beyond advancing novel therapeutics to address the medical challenges faced by people living with rare, serious autoimmune and inflammatory conditions, such as lupus nephritis, we work to advocate alongside patients and care partners, connect with the community to fully understand their needs, and provide educational resources and support.

Inspired by patients, we are driven to make an impact.

US-NA-2100071 04/2021

Social icon Square

Only use blue and/or white.

For more details check out our Learn more about Aurinia at www.auriniapharma.com Brand Guidelines. ExhibitFor more Guide information about lupus nephritis, visitOhio Aurinia’s Association ALL IN™ o ffor Rheumatology Lupus Nephritis program 16th Annual Meeting 4 www.allinforlupusnephritis.com EXHIBIT HALL FLOOR PLAN

Company Name Table # Company Name Table # AbbVie 2 Janssen Biotech, Inc. 5 Alexion Pharmaceuticals 17 Lilly USA, LLC 19 Alliance for Patient Access 20 Mallinckrodt Pharmaceuticals 25 Amgen 22, 23 Myriad Genetics 12 AstraZeneca 26 Novartis 3, 4 Aurinia Pharma U.S., Inc. 24 Pfizer, Inc 14 AWIR 18 Scipher Medicine 8 Boehringer Ingelheim, Inc. 21 SoundRheum Diagnostics 10 Bristol-Myers Squibb 9 TheraTest Laboratories, Inc. 7 Genentech 11 UCB, Inc. 1 GlaxoSmithKline 6 Ultragenyx 13 Horizon Therapeutics 15, 16

Transforming the language of life into vital medicines

At Amgen, we believe that the answers to medicine's most pressing questions are written in the langauge of our DNA. As pioneers at biotechology, we use our deep understanding of that language to create vital medicines that address the unmet medical needs of patients fighting serious illness-to dramatically improve their lives.

At UCB, everything we do starts with a simple question: “How will this create value for people living with severe diseases?” UCB is committed to advancing research to improve the lives of people living with autoimmune diseases and finding solutions to help patients achieve their goals.

Patients with HPP may experience unpredictable, devastating, and life-limiting consequences, including:1

PREMATURE SHORT STATURE MUSCLE WEAKNESS CHRONIC MUSCLE/ SKELETAL TOOTH LOSS AND/OR UNUSUAL AND/OR FATIGUE JOINT PAIN DEFORMITIES AND/ GAIT OR FRACTURES

• In adults, LOW ALP activity is <40 U/L2,a • Age- and sex-adjusted ALP reference intervals must be used in children3,4 Patients with any of these key signs/symptoms and LOW ALP should be evaluated for HPP1 aExample cutoff from Abbott Laboratories; adult ALP ranges are lab specific and may vary. References: 1. Bishop N, et al. Arch Dis Child. 2016;101(6):514-515. 2. Alkaline phosphatase [package insert]. Abbott Park, IL: Abbott Laboratories; 2007. 3. Offiah AC, et al. Pediatr Radiol. 2019;49(1):3-22. 4. Colantonio DA, et al. Clin Chem. 2012;58(5):854-868.

LOW Alkaline Phosphatase (ALP) may not be flagged if your laboratory does not use age- and sex-adjusted reference intervals in children when testing ALP activity1

Age- and sex-adjusted ALP reference ranges, U/L2,3

600 Females Males

500 518 518 517 460 460 400 369 369 365 300 273 280 273 200 ALP Activity, U/L 164 Normal ALP 156 141 156 141 150 100 134 128 134 127 90 95 90 89 Low ALP in pediatric females and males 62 59 54 48 40 0 Low ALP in adults a

0-14 d 1-<10 y 0-14 d 1-<10 y Adults 15 d-<1 y 10-<13 y13-<15 y 15-<17 y 17-<19 y 15 d-<1 y 10-<13 y13-<15 y 15-<17 y 17-<19 y Age

NOTE: Graph adapted from the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) project.2 Caliper samples from 1072 male and 1116 female participants (newborn to 18 years) were used to calculate age- and sex-specific reference intervals. No variation in ALP based on ethnic differences was observed. Reference intervals shown were established on the Abbott ARCHITECT c8000 analyzer. aAdult interval provided by the Abbott ARCHITECT ALP product information sheet is for females >15 and males >20 years of age. For younger ages, Abbott does not provide lower limits of normal.3

LOW Alkaline Phosphatase (ALP) is hallmark of Hypophosphatasia.1 To learn more, please visit www.hypophosphatasia.com

References: 1. Rockman-Greenberg C. Pediatr Endocrinol Rev. 2013;10(2 suppl):380-388. 2. Colantonio DA, et al. Clin Chem. 2012;58(5):854-868. 3. Alkaline phosphatase [package insert]. Abbott Park, IL: Abbott Laboratories; 2007.

Alexion is a registered trademark of Alexion Pharmaceuticals, Inc. Please contact [email protected] Copyright © 2020, Alexion Pharmaceuticals, Inc. All rights reserved. to learn more information about hypophosphatasia. US/UNB-H/0095

COMMITTED TO SUPPORTING PATIENTS WITH INFLAMMATORY DISEASES

SYN-C0SR-8985_Novartis Live Conference BW Ad_v01.indd 1 5/11/21 4:19 PM

Johnson & Johnson Health Care Systems Inc. © JJHCS Inc. 2020 The image depicted contains models and is being used for illustrative purposes only. Creating a future where disease is a thing of the past. We are Janssen, the Pharmaceutical Companies of Johnson & Johnson. We are focused on treating and preventing some of the most complex and devastating diseases of our time in oncology, immunology, neuroscience, infectious diseases & vaccines, cardiovascular & metabolism, and pulmonary hypertension. We pursue the most promising science, wherever it might be found. Learn more at www.janssen.com.

February 2020 cp-135770v1 2021 Promotional Partners

PLATINUM LEVEL PARTNERS

GOLD LEVEL PARTNERS

SILVER LEVEL PARTNERS